Viridian Therapeutics EBITDA 2014-2021 | VRDN

Viridian Therapeutics ebitda from 2014 to 2021. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Viridian Therapeutics Annual EBITDA
(Millions of US $)
2020 $-110
2019 $-42
2018 $-33
2017 $-26
2016 $-17
2015 $-11
2014 $-7
2013 $-0
Viridian Therapeutics Quarterly EBITDA
(Millions of US $)
2021-09-30 $-14
2021-06-30 $-18
2021-03-31 $-18
2020-12-31 $-90
2020-09-30 $-5
2020-06-30 $-6
2020-03-31 $-8
2019-12-31 $-10
2019-09-30 $-12
2019-06-30 $-9
2019-03-31 $-12
2018-12-31 $-11
2018-09-30 $-9
2018-06-30 $-9
2018-03-31 $-5
2017-12-31 $-6
2017-09-30 $-6
2017-06-30 $-7
2017-03-31 $-7
2016-12-31 $-6
2016-09-30 $-4
2016-06-30 $-3
2016-03-31 $-3
2015-12-31 $-3
2015-09-30 $-3
2015-06-30 $-2
2015-03-31 $-3
2014-12-31 $-2
2014-09-30 $-2
2014-06-30 $-3
2014-03-31 $-0
2013-12-31 $0
2013-09-30 $-0
2013-06-30 $-0
2013-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.390B $0.001B
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.281B 7.66
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.681B 21.48
Biohaven Pharmaceutical Holding (BHVN) United States $7.357B 0.00
Arcus Biosciences (RCUS) United States $3.170B 0.00
Emergent Biosolutions (EBS) United States $2.265B 8.14
Myovant Sciences (MYOV) United Kingdom $1.741B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.500B 0.00
Zymeworks (ZYME) Canada $0.902B 0.00
Ambrx Biopharma (AMAM) United States $0.391B 0.00
SQZ Biotechnologies (SQZ) United States $0.337B 0.00
Enzo Biochem (ENZ) United States $0.162B 15.95